Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months. - Université de Bretagne Occidentale Access content directly
Conference Poster Year : 2019
No file

Dates and versions

hal-02151122 , version 1 (07-06-2019)

Identifiers

  • HAL Id : hal-02151122 , version 1

Cite

Alain Saraux, Thomas Barnetche, Guy Baudens, Isabelle Idier, Flore Delaporte, et al.. Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.. EULAR 2019, Jun 2019, MADRID, Spain. ⟨hal-02151122⟩
26 View
0 Download

Share

Gmail Mastodon Facebook X LinkedIn More